

SU11274

Catalog No: tcsc0144



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

658084-23-2

Formula:

$C_{28}H_{30}ClN_5O_4S$

Pathway:

Protein Tyrosine Kinase/RTK;Autophagy

Target:

c-Met/HGFR;Autophagy

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

PKI-SU11274

Observed Molecular Weight:


568.09

Product Description

SU11274 is a selective **Met** inhibitor with **IC₅₀** of 10 nM, but has no effects on PDGFR β , EGFR or Tie2.

IC50 & Target: IC50: 10 nM (Met)^[1]

In Vitro: SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3 β . SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC₅₀ of 50 of 1-1.5 μ M. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC₅₀ of 3.4 μ M and 6.5 μ M, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μ M, and induces caspase-dependent apoptosis by 24% at 1 μ M^[2]. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC₅₀ values of 0.8-4.4 μ M, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!